Kamalakannan Palanichamy PhD

Kamalakannan Palanichamy PhD
Res Asst ProfessorCollege of Medicinepalanichamy.1@osu.edu
385E Wiseman Hall 400 W 12th Avenue Columbus Ohio 43210
Phone:614-247-6393Fax: (614) 292-5435
  • Translational Therapeutics

Research Description

Dr. Palanichamy's research includes: Identifying Underlying Mechanisms of Radiation Resistance in Treatment Refractory Tumors, Cancer Stem Cells, Exploiting Protein-Protein Interactions at Transcriptional and Translational Level and Identifying New Therapeutic Targets, and Integrative OMICS

Current Publications

  • Kim TH, Song J, Kim SH, Parikh AK, Mo X, Palanichamy K, Kaur B, Yu J, Yoon SO, Nakano I, Kwon CHPiperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells.Neuro Oncol 16 1354-64 10/1/2014
  • Meng W, McElroy JP, Volinia S, Palatini J, Warner S, Ayers LW, Palanichamy K, Chakravarti A, Lautenschlaeger TComparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues.PLoS One 8 e64393 1/1/2013
  • Waters JD, Sanchez C, Sahin A, Futalan D, Gonda DD, Scheer JK, Akers J, Palanichamy K, Waterman P, Chakravarti A, Weissleder R, Morse B, Marsh N, Furfine E, Chen CC, Carvajal I, Carter BSCT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.J Neurooncol 110 37-48 10/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu